Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anthrax CVD 3000
NCT00133484Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of anthrax rPA vaccine in anthrax (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Proportion of volunteers with a 4-fold or greater increase in anti-rPA IgG antibody. Status: terminated.
02
Drugs
anthrax rPA vaccine
03
Conditions
anthrax
Beyond the preview
Go deeper on NCT00133484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133484.